Getein Biotech Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	no data
Board average tenure	3.3yrs

Recent management updates

Recent updates

CEO

Getein Biotech has no CEO, or we have no data on them.

Board Members

Name	Position	Tenure	Compensation	Ownership
Gang Zhu	Deputy GM & Director	3.3yrs	CN¥904.60k	no data
Xingde Zhuo	Director	no data	no data	no data
Honghai Yu	Independent Director	3.3yrs	CN¥100.00k	no data
Suiren Wan	Independent Director	3.3yrs	CN¥100.00k	no data
Jing Luo	Independent Director	1.6yrs	CN¥25.00k	no data
Jun Chen	Independent Director	3.3yrs	no data	no data
Jing Li	Chairman of the Supervisory Board	9.4yrs	CN¥100.00k	no data
Wu Zhang	Supervisor	3.3yrs	no data	no data

3.3yrs

Average Tenure

45yo

Average Age

Experienced Board: 603387's board of directors are considered experienced (3.3 years average tenure).

Getein Biotech Management

Management criteria checks 1/4

Key information

Recent management updates

High number of new and inexperienced directors

Recent updates

Getein Biotech, Inc to Report Q1, 2024 Results on Apr 27, 2024

Investor sentiment deteriorates as stock falls 17%

Getein Biotech, Inc to Report Fiscal Year 2023 Results on Apr 27, 2024

Third quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.28 in 3Q 2022)

High number of new and inexperienced directors

Now 20% undervalued after recent price drop

Second quarter 2023 earnings released: EPS: CN¥0.091 (vs CN¥0.22 in 2Q 2022)

Getein Biotech, Inc to Report First Half, 2023 Results on Aug 29, 2023

Now 21% undervalued

Full year 2022 earnings released: EPS: CN¥0.97 (vs CN¥0.79 in FY 2021)

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.28 (vs CN¥0.16 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.22 (vs CN¥0.22 in 2Q 2021)

Full year 2021 earnings released: EPS: CN¥1.10 (vs CN¥0.84 in FY 2020)

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.23 (vs CN¥0.27 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.30 (vs CN¥0.24 in 2Q 2020)

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.24 (vs CN¥0.12 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥1.20 (vs CN¥1.31 in FY 2019)

New 90-day low: CN¥30.30

New 90-day low: CN¥30.80

New 90-day low: CN¥34.80

Third quarter earnings released

New 90-day high: CN¥41.89

First half earnings released

Getein Biotech, Inc (SHSE:603387) completed the acquisition of 54.96% stake in Wuhan King Diagnostic Technology Co.,Ltd. from a group of 21 sellers.

Getein Biotech, Inc to Report First Half, 2020 Results on Aug 27, 2020

CEO

Board Members

Average Tenure

Average Age